Did you know getting enough high quality sleep could help protect against developing neurological diseases including Alzheimer’s? This episode delves into the groundbreaking research our guests are doing in the intersection between sleep and neurodegeneration. 

Hosted on Acast. See acast.com/privacy for more information.

This episode delves into the critical gaps in therapeutic options for the more than 300 million people living with rare diseases worldwide and explores why this field is rapidly gaining attention from both researchers and investors.

Our guests also share insights into their life‑changing work across brittle bone disease, oncology, and fragile X syndrome, highlighting the breakthroughs that are bringing new hope to patients and families.

Hosted on Acast. See acast.com/privacy for more information.

This celebratory episode of the #OptimumPerspectivesPodcast explores how female venture capitalists are shaping the future of science, technology, and innovation, and why who funds science matters almost as much as who does the science. 

Listen to the full episode featuring Victoria Taylor of Medicxi, Bonnie van Wilgenburg of Monograph Capital and Noga Yerushalmi of M Ventures.

#IDWGIS2026 #WomeninSTEM

Hosted on Acast. See acast.com/privacy for more information.

Hear from Jennifer Schneider of Centauri Therapeutics, Franz-Werner Haas of LimmaTech Biologics and Neil Murray of ReNewVax on their unique approaches to tackling the threat of AMR, in the latest episode of the Optimum Perspectives Podcast.

Hosted on Acast. See acast.com/privacy for more information.

Join Francois Bertelli of DISCO Pharmaceuticals, Stefano Gulla of Kling Biotherapeutics, and Michael Bauer of Novo Holdings, as they dive into the hot topic: ‘The ups and downs of ADCs – where to now?’

Expect sharp insights and forward-looking perspectives on the evolving ADC landscape. Listen to the full episode here.

Hosted on Acast. See acast.com/privacy for more information.

Listen as Caroline details the devastating effects of Huntington’s Disease on patients and families, her personal motivations for working in this therapeutic area, as well as LoQus23’s unique approach to battling the disease through their innovative small molecule approach.

Hosted on Acast. See acast.com/privacy for more information.

Listen below as Ali reflects on his scientific journey which has led him to this tremendous recognition, from what inspired his passion for science, to how he came to meet Curve CEO Simon Kerry, with whom he co-founded the Company. Curve’s is using its revolutionary gene-encoded Microcycle® platform to build a pipeline of innovative cyclic peptide and small molecule drugs addressing intracellular targets, with a focus on cancer, immunology and inflammation.

Hosted on Acast. See acast.com/privacy for more information.

This emotional yet hopeful episode highlights the importance of raising awareness of rare conditions, while discussing patient care, diagnosis, and genetic testing for Muscular Dystrophy.

If you would like to contribute to the life changing work of Muscular Dystrophy UK, or find out more about Tahira's story living with GNE myopathy, visit her page here: Tahira's Team - JustGiving

Hosted on Acast. See acast.com/privacy for more information.

In the latest episode of Optimum Perspectives, hear from Benoit Cugnet, Head of Fiber Business Unit at AMSilk, on how this German biotech is changing the face of advanced materials.

Hosted on Acast. See acast.com/privacy for more information.

Hear from Lynn Lewis, CEO of Gilmartin Group, Optimum’s US partner, on the considerations and milestones to reach before listing.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

In this in-depth podcast, CEO Simon Kerry describes how investors fell in love with Curve’s “Microcycle” based discovery platform, which gives the company “the ability to potentially identify drugs against very difficult, challenging targets”.

He explains how Curve’s platform enables them to spot drugs with a higher chance of working in real-world conditions. He also outlines the firm’s lead programme – which aims to block two cancer targets called Hypoxia Inducible Factors, or “HIFs”, which enable solid tumours to survive in low-oxygen conditions.

Speaking to Optimum’s Stephen Adams, Simon ponders the role of luck in securing investment, both “the kind you deserve because you turn over a lot of stones”, and the more fortuitous variety.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Chaired by esteemed journalist Lisa Urquhart, hear guest speakers Renee Aguiar-Lucander of Calliditas, Lene Gerlach of EIR Ventures & WiLD, Bita Sehat of Trill Impact, and Ninna Struck Rossen of Metsystem, share their stories on being women in life sciences, and how to succeed in the industry.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

4SC is a late-stage biotech improving lives for patients suffering with advanced-stage Cutaneous T Cell Lymphoma (CTCL).

It has developed Kinselby (resminostat), a novel, oral, maintenance treatment targeting advanced-CTCL, a rare type of non-Hodgkin lymphoma that affects the skin. There are no drugs in development or on the market as maintenance therapy for CTCL.

Kinselby (resminostat) is an orally administered histone deacetylase (HDAC) inhibitor that has produced supportive results in the pivotal RESMAIN trial, where it postponed disease progression in patients – a new treatment paradigm in CTCL.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

Alchemab specifically looks to identify shared antibodies from people who have shown resilience to disease – the unexpectedly well. The company then uses its proprietary technology to identify which targets these antibodies are binding to, and what diseases these targets are associated with.  

Optimum Strategic Communications’ Richard Staines caught up with Alchemab’s CEO, Young Kwon, to find out more. 

Hosted on Acast. See acast.com/privacy for more information.

Optimum Strategic Communications’ Richard Staines interviewed CEO Jeremy Skillington to find out how Poolbeg is using AI to expedite discovery of new flu drugs.

Poolbeg is working on a drug that aims to block some of the worst effects of influenza, neutralising the over-reaction from the body’s immune system known as a “cytokine storm” that produces many of the ill effects following a flu infection. 

Hosted on Acast. See acast.com/privacy for more information.

Hosted on Acast. See acast.com/privacy for more information.

In these circumstances, obtaining the right backing – both in terms of finance and managerial advice – is more important than ever. 

In the fifth Optimum Perspectives podcast experienced investor Søren Møller talks to Optimum’s Stephen Adams about Novo Holdings Seed Investments’ approach to working with biotechs and what early-stage companies should look for in a financing partner. 

Hosted on Acast. See acast.com/privacy for more information.

Listen to Renée Aguiar-Lucander, CEO of Calliditas Therapeutics, tell Optimum’s Richard Staines how they brought TARPEYO, the first FDA-approved drug for the rare kidney disease primary IgA nephropathy, to market.

She describes her ‘incredible journey’ growing the firm from less than 10 staff to more than 200, taking it public in Europe and the US, running a global Phase III trial, and how Tarpeyo can help people with IgA nephropathy live more normal lives.

https://www.optimumcomms.com/podcast

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.

https://www.optimumcomms.com/podcast

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.

Yet, despite this, treatment options are limited, held back by a lack of research into medical products focused on women’s health. 

Versameb, hopes to change this with a novel mRNA therapy that rebuilds the urinary sphincter and is about to enter clinical trials. In this podcast, Richard Staines from Optimum Strategic Communications caught up with the Versameb team to find out more. Read the insight piece here: Versameb: Revolutionizing SUI therapy with mRNA technology

https://www.optimumcomms.com/podcast / https://versameb.com/

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.

In our first episode, we hear from Jan Ross, a patient who discusses the pressing need for new therapies for multiple myeloma with fewer side effects. We also talked to top cancer experts – Tim Somervaille of the Christie Hospital in Manchester, Karen Knudsen, Chief Executive of the American Cancer Society, Dr Leif Bergsagel, consultant in the Division of Hematology and Medical Oncology, at the Mayo Clinic in Arizona, and Will West, CEO of CellCentric.

Despite recent medical advances, treating haematological cancer remains a considerable challenge. CAR-T cell therapies have shown incredible efficacy against some forms of blood cancer, but side-effects are fearsome, and they don’t always work. Conventional therapies may require injections and regular inconvenient visits to the hospital. And CAR-T cell therapies are hugely expensive for healthcare systems to buy and administer to patients because of the workload for staff monitoring side effects. A UK biotech, CellCentric has seen an opening for an oral therapy, based on a small molecule drug, that could treat multiple myeloma and could be taken by patients in their own home.

https://www.optimumcomms.com/podcast / www.cellcentric.com

Follow us and subscribe for new episodes highlighting the latest innovation and developments in life sciences, with industry leaders of the healthcare sector.

Available on all major platforms: Apple, Spotify, Google, Amazon Music, Tune In, Castbox, Deezer and more! 

Follow and Subscribe today. #optimumperspectivespodcast

Hosted on Acast. See acast.com/privacy for more information.